Clinical usefulness of percentage of free serum prostate specific antigen

Clinica Chimica Acta

Volumn 258, Issue 1, 1997, Pages 79-90

  Vogl, M ^a   Muller M M ^a   Holtl W ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Percentage of free prostate specific antigen; Prostate cancer screening; Total prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TECHNIQUE;

ADENOCARCINOMA; BIOLOGICAL MARKERS; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN BINDING;

EID: 0031550608     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(96)06449-2     Document Type: Article

References (16)

1. [1] Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol 1979;17:159-163.
2. [2] Lilja H, Oldbrink J, Ramevik G, Camell CB. Seminal vesicle secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987;80:281-285.
3. [3] Lilja H. Significances of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to α-1-antichymotrypsin. Urol Clin N Am 1993;20:681-686.
4. [4] Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
5. [5] Hetherington JW, Siddall JK, Cooper EH. Contribution of bone scintigraphy, prostatic acid phosphatase and prostatic-specific antigen to the monitoring of prostatic cancer. Eur Urol 1988;14:11-15.
6. [6] Oesterling JE, Chan DW, Epstein JI et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-772.
7. [7] Chodak CW, Schoenberg HW. Progress and problems in screening for carcinoma of the prostate. World J Surg 1989;13:60-64.
8. [8] Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994;151:1283-1290.
9. [9] Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J Am Med Assoc 1995;274:1214-1220.
10. [10] Prestigiacomo AF, Stamey TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest 1995;55(Suppl 221):32-34.
11. [11] Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324:236-245.
12. [12] Diamandis EP. New diagnostic applications and physiological functions of prostate specific antigen. Scand J Clin Lab Invest 1995;55(Suppl 221):105-112.
13. [13] McLachlin SM, Srigley JR. Prostatic tissue in mature cystic teratomas of the ovary. Am J Surg Pathol 1992;16:780-784.
14. [14] Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
15. [15] Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α-1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-1598.
16. [16] Lilja H. Ratio of Free and Complexed PSA improves Distinction of Prostate Cancer and Benign Prostatic Hyperplasia. Berlin: XIth Congress of the European Association of Urology, 1994. Edited by Scientific Affairs Europe, Germany.